在 2 家肿瘤皮肤科诊所就诊的患者中免疫治疗相关瘙痒的临床特征。
Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics.
机构信息
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Dermatology Service, Hospital Vithas Santa Catalina, Gran Canaria, Spain.
出版信息
JAMA Dermatol. 2019 Feb 1;155(2):249-251. doi: 10.1001/jamadermatol.2018.4560.
Abstract
This cohort study assesses self-reported quality of life among patients referred to oncodermatology clinics for pruritus associated with immunotherapy.
摘要
本队列研究评估了因免疫治疗相关瘙痒而就诊于肿瘤皮肤科诊所的患者的自我报告生活质量。
相似文献
1
Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics.在 2 家肿瘤皮肤科诊所就诊的患者中免疫治疗相关瘙痒的临床特征。
JAMA Dermatol. 2019 Feb 1;155(2):249-251. doi: 10.1001/jamadermatol.2018.4560.
2
Update on primary mucosal melanoma.原发性黏膜黑色素瘤的最新进展。
J Am Acad Dermatol. 2014 Aug;71(2):366-75. doi: 10.1016/j.jaad.2014.03.031. Epub 2014 May 6.
3
Primary extracutaneous malignant melanoma: a comprehensive review with emphasis on treatment.原发性皮肤外恶性黑色素瘤：一项侧重于治疗的综合综述
Onkologie. 2004 Oct;27(5):492-9. doi: 10.1159/000080372.
4
A multiphase immunotherapy regimen for human melanoma: clinical and laboratory results.一种用于人类黑色素瘤的多阶段免疫治疗方案：临床和实验室结果。
Cancer. 1974 Oct;34(4 Suppl):suppl:1548-57. doi: 10.1002/1097-0142(197410)34:8+<1548::aid-cncr2820340829>3.0.co;2-t.
5
A Huge Melanoma.一个巨大的黑色素瘤。
Isr Med Assoc J. 2015 Dec;17(12):787-8.
6
Immunotherapy for melanoma.黑色素瘤的免疫疗法。
Cancer Control. 2002 Jan-Feb;9(1):22-30. doi: 10.1177/107327480200900104.
7
Desmoplastic melanoma: a brief review and the efficacy of immunotherapy.促纤维增生性黑色素瘤：简要综述及免疫治疗疗效
Expert Rev Anticancer Ther. 2019 Mar;19(3):205-207. doi: 10.1080/14737140.2019.1574573. Epub 2019 Feb 4.
8
Melanoma: is immunotherapy of benefit?黑色素瘤：免疫疗法有益吗？
Adv Surg. 2003;37:139-69.
9
In situ photoimmunotherapy: a surgery- and limb-sparing approach to the treatment of cutaneous metastases in advanced melanoma.原位光免疫疗法：一种治疗晚期黑色素瘤皮肤转移的保留手术和肢体的方法。
Arch Dermatol. 2010 Aug;146(8):831-4. doi: 10.1001/archdermatol.2010.181.
10
Cutaneous toxicities of new treatments for melanoma.新型黑素瘤治疗药物的皮肤毒性。
Clin Transl Oncol. 2018 Nov;20(11):1373-1384. doi: 10.1007/s12094-018-1891-7. Epub 2018 May 24.
引用本文的文献
1
The Treatment of Pembrolizumab-Induced Pruritus with Topical Roflumilast Cream 0.3% Once Daily.每日一次外用0.3%罗氟司特乳膏治疗帕博利珠单抗引起的瘙痒
J Clin Aesthet Dermatol. 2025 May 1;18(5):36-37.
2
Dermatologic toxicities related to cancer immunotherapy.与癌症免疫治疗相关的皮肤毒性
Toxicol Rep. 2025 Apr 5;14:102021. doi: 10.1016/j.toxrep.2025.102021. eCollection 2025 Jun.
3
Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence.免疫检查点抑制剂相关的皮肤不良事件：发生机制
Int J Mol Sci. 2024 Dec 26;26(1):88. doi: 10.3390/ijms26010088.
4
The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases.生物制剂在治疗免疫检查点抑制剂相关皮肤免疫相关不良事件中的应用：病例报告综述。
Am J Clin Dermatol. 2024 Jul;25(4):595-607. doi: 10.1007/s40257-024-00866-z. Epub 2024 May 20.
5
The regulation of the PD-1/PD-L1 pathway in imiquimod-induced chronic psoriasis itch and itch sensitization in mouse.咪喹莫特诱导的小鼠慢性银屑病瘙痒及瘙痒致敏中PD-1/PD-L1通路的调控
Mol Pain. 2024 Jan-Dec;20:17448069241252384. doi: 10.1177/17448069241252384.
6
The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature.皮肤科不良事件对肿瘤患者生活质量的影响：文献综述。
Am J Clin Dermatol. 2024 May;25(3):435-445. doi: 10.1007/s40257-024-00847-2. Epub 2024 Feb 16.
7
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients.曲妥珠单抗和帕妥珠单抗相关的 HER2 阳性乳腺癌患者瘙痒。
Breast Cancer Res Treat. 2024 Jan;203(2):271-280. doi: 10.1007/s10549-023-07143-3. Epub 2023 Oct 13.
8
Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors.免疫检查点抑制剂诱导的皮肤免疫相关不良事件（irAEs）的分子机制。
Curr Oncol. 2023 Jul 18;30(7):6805-6819. doi: 10.3390/curroncol30070498.
9
Cutaneous manifestations associated with immune checkpoint inhibitors.与免疫检查点抑制剂相关的皮肤表现。
Front Immunol. 2023 Feb 20;14:1071983. doi: 10.3389/fimmu.2023.1071983. eCollection 2023.
10
Cutaneous adverse events in patients treated with PD-1/PD-L1 checkpoint inhibitors and their association with survival: a systematic review and meta-analysis.PD-1/PD-L1 检查点抑制剂治疗患者的皮肤不良反应及其与生存的关系：系统评价和荟萃分析。
Sci Rep. 2022 Nov 21;12(1):20038. doi: 10.1038/s41598-022-24286-3.
本文引用的文献
1
Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis.抗PD-1和抗PD-L1药物的免疫相关不良事件：系统评价与荟萃分析
BMJ. 2018 Mar 14;360:k793. doi: 10.1136/bmj.k793.
2
Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.免疫检查点抑制剂的皮肤不良反应：皮肤毒性与免疫治疗
Am J Clin Dermatol. 2018 Jun;19(3):345-361. doi: 10.1007/s40257-017-0336-3.
3
Prevalence of chronic itch and associated factors in haemodialysis patients: a representative cross-sectional study.血液透析患者慢性瘙痒的患病率及相关因素：一项代表性横断面研究。
Acta Derm Venereol. 2015 Sep;95(7):816-21. doi: 10.2340/00015555-2087.
4
Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0.癌症治疗相关皮肤不良反应分级：不良事件通用术语标准 4.0 版。
J Am Acad Dermatol. 2012 Nov;67(5):1025-39. doi: 10.1016/j.jaad.2012.02.010. Epub 2012 Apr 11.
5
The impact of pruritus on quality of life: the skin equivalent of pain.瘙痒对生活质量的影响：皮肤层面的疼痛等效物。
Arch Dermatol. 2011 Oct;147(10):1153-6. doi: 10.1001/archdermatol.2011.178. Epub 2011 Jun 16.
6
A pilot quality-of-life instrument for pruritus.一种用于瘙痒症的生活质量简易评估工具。
J Am Acad Dermatol. 2008 Aug;59(2):234-44. doi: 10.1016/j.jaad.2008.04.006. Epub 2008 Jun 11.
Zotero 插件